Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

6.200 -0.040 (-0.64%)
Streaming Delayed Price Updated: 11:06 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 3 4 Next >
News headline image
What's Going On With Sagimet Biosciences Stock On Thursday? ↗
Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress. 
Via Benzinga
News headline image
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
News headline image
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH 
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 ↗
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
News headline image
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China ↗
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning! 
Via InvestorPlace
News headline image
KLA Reports Q2 Results, Joins Visa, Western Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning. 
Via InvestorPlace
News headline image
Texas Instruments Reports Q4 Results, Joins BlackBerry And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Wednesday. 
Via Benzinga
News headline image
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.